|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
Dobutamine results in decreased activity of ABCB11 protein |
CTD |
PMID:28437613 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Adcy6 |
adenylate cyclase 6 |
affects response to substance |
ISO |
ADCY6 protein affects the susceptibility to Dobutamine |
CTD |
PMID:12393090 |
|
NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
Dobutamine binds to and results in increased activity of ADRA2A protein |
CTD |
PMID:16024912 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
affects response to substance multiple interactions |
ISO EXP |
ADRB1 gene affects the susceptibility to Dobutamine; ADRB1 gene polymorphism affects the susceptibility to Dobutamine; ADRB1 protein polymorphism affects the susceptibility to Dobutamine ADRB1 gene polymorphism affects the susceptibility to [Dobutamine co-treated with Metoprolol]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine binds to and results in increased activity of ADRB1 protein; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 mRNA; [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 protein; Dobutamine binds to and results in increased activity of ADRB1 protein; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Oxygen deficiency results in increased susceptibility to [Dobutamine binds to and results in increased activity of ADRB1 protein] |
CTD |
PMID:8096834 PMID:10192281 PMID:11753577 PMID:14502278 PMID:15564877 PMID:16024912 PMID:18787115 PMID:19719783 PMID:20821015 PMID:21311897 More...
|
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
affects response to substance |
ISO |
ADRB2 gene polymorphism affects the susceptibility to Dobutamine |
CTD |
PMID:17094270 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
EXP |
[Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 mRNA; [Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 protein |
CTD |
PMID:19719783 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
affects response to substance |
ISO |
AHSG protein affects the susceptibility to Dobutamine |
CTD |
PMID:16177000 |
|
NCBI chr11:78,121,388...78,127,998
Ensembl chr11:78,117,918...78,145,999
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects response to substance multiple interactions |
ISO EXP |
AKT1 protein affects the susceptibility to Dobutamine Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:16094411 PMID:16339297 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
EXP |
Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein] |
CTD |
PMID:16339297 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
multiple interactions |
EXP |
Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein] |
CTD |
PMID:16339297 |
|
NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:18787115 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:18787115 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Dobutamine results in increased expression of BAX protein |
CTD |
PMID:15052282 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Dobutamine results in decreased expression of BCL2 protein |
CTD |
PMID:15052282 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bnip1 |
BCL2 interacting protein 1 |
increases expression |
ISO |
Dobutamine results in increased expression of BNIP1 protein |
CTD |
PMID:15052282 |
|
NCBI chr10:16,386,876...16,399,124
Ensembl chr10:16,386,841...16,399,157
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein] |
CTD |
PMID:12818967 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein] |
CTD |
PMID:12818968 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
Dobutamine results in increased expression of CLU protein |
CTD |
PMID:15052282 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Comt |
catechol-O-methyltransferase |
increases methylation increases expression |
ISO EXP |
COMT protein results in increased methylation of Dobutamine Dobutamine results in increased expression of COMT mRNA |
CTD |
PMID:11160877 PMID:12423672 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
EXP |
Dobutamine results in increased expression of CPT1A mRNA; Dobutamine results in increased expression of CPT1A protein |
CTD |
PMID:8479178 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crem |
cAMP responsive element modulator |
affects response to substance |
ISO |
CREM protein affects the susceptibility to Dobutamine |
CTD |
PMID:12475904 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Ctf1 |
cardiotrophin 1 |
affects response to substance |
ISO |
CTF1 protein affects the susceptibility to Dobutamine |
CTD |
PMID:17150369 |
|
NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA] |
CTD |
PMID:11605937 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Dbh |
dopamine beta-hydroxylase |
affects response to substance |
ISO |
DBH protein affects the susceptibility to Dobutamine |
CTD |
PMID:10338466 |
|
NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248
|
|
G |
Dmd |
dystrophin |
increases response to substance |
ISO |
DMD gene mutant form results in increased susceptibility to Dobutamine |
CTD |
PMID:17440445 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases response to substance multiple interactions |
ISO |
EGFR gene mutant form results in decreased susceptibility to Dobutamine AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] |
CTD |
PMID:18599591 PMID:18787115 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Dobutamine binds to and results in increased activity of ESR1 protein |
CTD |
PMID:24928891 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Dobutamine results in increased expression of F3 protein |
CTD |
PMID:16286589 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects response to substance |
ISO |
FGF2 protein affects the susceptibility to Dobutamine |
CTD |
PMID:10491406 PMID:14583313 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases activity |
EXP |
Dobutamine results in increased activity of G6PD protein |
CTD |
PMID:1978808 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
EXP |
GH1 protein promotes the reaction [Dobutamine results in increased metabolism of Lipids] |
CTD |
PMID:14981226 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gk |
glycerol kinase |
increases activity |
EXP |
Dobutamine results in increased activity of GK protein |
CTD |
PMID:12736183 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Gnas |
GNAS complex locus |
increases response to substance |
ISO |
GNAS gene SNP results in increased susceptibility to Dobutamine |
CTD |
PMID:19542315 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
affects response to substance |
ISO |
GSK3B gene mutant form affects the susceptibility to Dobutamine |
CTD |
PMID:17901358 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] |
CTD |
PMID:18787115 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP |
esmolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein] Dobutamine results in increased expression of HMOX1 mRNA; Dobutamine results in increased expression of HMOX1 protein |
CTD |
PMID:15179140 PMID:16627864 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases response to substance |
EXP |
IGF1 protein results in increased susceptibility to Dobutamine |
CTD |
PMID:17184500 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Dobutamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL10 protein] Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein] |
CTD |
PMID:11605937 PMID:15502056 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
increases expression decreases expression |
EXP ISO |
Dobutamine results in increased expression of IL1B mRNA Dobutamine results in decreased expression of IL1B mRNA |
CTD |
PMID:9387890 PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions decreases expression |
ISO EXP |
Dobutamine results in increased expression of IL6 protein Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] Dobutamine results in decreased expression of IL6 mRNA |
CTD |
PMID:11605937 PMID:12423672 PMID:16286589 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb1 |
integrin subunit beta 1 |
affects response to substance |
ISO |
ITGB1 protein affects the susceptibility to Dobutamine |
CTD |
PMID:11884376 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Dobutamine results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions affects response to substance |
ISO |
KCNJ11 protein affects the reaction [[Manganese co-treated with Dobutamine] results in increased abundance of Calcium] KCNJ11 protein affects the susceptibility to Dobutamine |
CTD |
PMID:17189350 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Klk1 |
kallikrein 1 |
affects response to substance |
ISO |
KLK1 protein affects the susceptibility to Dobutamine |
CTD |
PMID:12411458 |
|
NCBI chr 1:94,642,644...94,646,760
Ensembl chr 1:94,642,687...94,646,754
|
|
G |
Lep |
leptin |
decreases secretion decreases expression |
ISO |
Dobutamine results in decreased secretion of LEP protein Dobutamine results in decreased expression of LEP mRNA; Dobutamine results in decreased expression of LEP protein |
CTD |
PMID:9002984 PMID:11022189 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
affects response to substance |
ISO |
LEPR protein affects the susceptibility to Dobutamine |
CTD |
PMID:20175764 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK1 protein Dobutamine results in increased phosphorylation of MAPK1 protein AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] |
CTD |
PMID:16760913 PMID:18787115 PMID:19719783 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK3 protein Dobutamine results in increased phosphorylation of MAPK3 protein AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:16760913 PMID:18787115 PMID:19719783 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK9 protein |
CTD |
PMID:19719783 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mb |
myoglobin |
affects response to substance |
ISO |
MB protein affects the susceptibility to Dobutamine |
CTD |
PMID:10468637 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Dobutamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein] |
CTD |
PMID:15502056 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos1 |
nitric oxide synthase 1 |
affects response to substance |
ISO |
NOS1 protein affects the susceptibility to Dobutamine |
CTD |
PMID:16344403 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
affects response to substance |
ISO |
NOS2 protein affects the susceptibility to Dobutamine |
CTD |
PMID:9396439 PMID:11489778 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases activity |
ISO |
Dobutamine results in increased activity of NR1H4 protein |
CTD |
PMID:22414727 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
increases expression |
EXP |
Dobutamine results in increased expression of PHGDH mRNA |
CTD |
PMID:12423672 |
|
NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Pln |
phospholamban |
affects response to substance |
ISO |
PLN protein affects the susceptibility to Dobutamine |
CTD |
PMID:14991071 |
|
NCBI chr20:32,629,537...32,639,559
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
affects response to substance |
ISO |
PPP2CA protein affects the susceptibility to Dobutamine |
CTD |
PMID:15247211 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein] |
CTD |
PMID:16339297 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkce |
protein kinase C, epsilon |
affects response to substance |
ISO |
PRKCE protein affects the susceptibility to Dobutamine |
CTD |
PMID:15242976 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prop1 |
PROP paired-like homeobox 1 |
decreases response to substance |
ISO |
PROP1 gene mutant form results in decreased susceptibility to Dobutamine |
CTD |
PMID:19414510 |
|
NCBI chr10:35,271,959...35,274,434
Ensembl chr10:35,271,973...35,274,434
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Dobutamine results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ren |
renin |
multiple interactions increases activity increases secretion increases expression |
ISO |
Cycloheximide inhibits the reaction [Dobutamine results in increased secretion of REN protein]; Dactinomycin inhibits the reaction [Dobutamine results in increased secretion of REN protein] Dobutamine results in increased activity of REN protein Dobutamine results in increased expression of REN mRNA |
CTD |
PMID:9203624 PMID:9209250 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
S100a1 |
S100 calcium binding protein A1 |
increases response to substance |
ISO |
S100A1 gene mutant form results in increased susceptibility to Dobutamine |
CTD |
PMID:18645228 |
|
NCBI chr 2:175,993,922...175,998,765
Ensembl chr 2:175,993,922...175,999,544
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
increases expression |
EXP |
Dobutamine results in increased expression of SCNN1G mRNA |
CTD |
PMID:16638327 |
|
NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816
|
|
G |
Sgcd |
sarcoglycan, delta |
affects response to substance |
ISO |
SGCD affects the susceptibility to Dobutamine |
CTD |
PMID:20675662 |
|
NCBI chr10:31,346,480...32,328,364
Ensembl chr10:31,280,511...31,724,840
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
increases degradation |
EXP |
Dobutamine deficiency results in increased degradation of SPTAN1 protein |
CTD |
PMID:15849228 |
|
NCBI chr 3:13,241,164...13,306,047
Ensembl chr 3:13,241,217...13,306,046
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
ISO |
Dobutamine promotes the reaction [TAC1 protein binds to and results in increased activity of TACR1 protein] |
CTD |
PMID:8994422 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tacr1 |
tachykinin receptor 1 |
multiple interactions |
ISO |
Dobutamine promotes the reaction [TAC1 protein binds to and results in increased activity of TACR1 protein] |
CTD |
PMID:8994422 |
|
NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
EXP |
Dobutamine results in increased expression of TGFB1 mRNA |
CTD |
PMID:16760913 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
EXP |
Dobutamine results in increased expression of TGFB2 mRNA |
CTD |
PMID:16760913 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression decreases secretion |
EXP |
Dobutamine results in decreased expression of TNF mRNA Dobutamine results in decreased secretion of TNF protein |
CTD |
PMID:12423672 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
decreases expression |
ISO |
Dobutamine results in decreased expression of TNFAIP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Usf1 |
upstream transcription factor 1 |
multiple interactions |
ISO |
USF1 gene polymorphism promotes the reaction [Dobutamine results in increased metabolism of Lipids]; USF1 protein affects the reaction [Dobutamine results in increased metabolism of Lipids] |
CTD |
PMID:15985485 |
|
NCBI chr13:83,845,230...83,854,875
Ensembl chr13:83,822,035...83,854,885
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects response to substance |
ISO |
VEGFA protein affects the susceptibility to Dobutamine |
CTD |
PMID:11599061 PMID:14583313 PMID:19237429 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|